Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032
Exploratory analysis shows stable health-related quality of life in multiple myeloma patients treated with daratumumab, indicating lasting efficacy and safety.
Key Points
Health-related quality of life remained stable in Chinese multiple myeloma patients after daratumumab therapy.
Median follow-up was 23.7 months, with favorable progression-free survival observed.
Assessment utilized mixed model for repeated measures analyzing EQ-5D-5D scores.
Improvements in fatigue and pain were noted at various time points, supporting overall treatment efficacy.